Follicular lymphoma (FL) is a systemic neoplasm of the lymphoid tissue displaying germinal
centre (GC) B cell differentiation. FL represents~ 5% of all haematological neoplasms and …

Follicular lymphoma (FL) represents a heterogeneous disease both clinically and
biologically. The pathognomonic t (14; 18) translocation can no longer be thought of as the …

The management of patients with relapsed or refractory follicular lymphoma has evolved
markedly in the last decade, with the availability of new classes of agents (phosphoinositide …

Follicular lymphoma (FL) is a heterogeneous disease with varying prognosis owing to
differences in clinical, laboratory, and disease parameters. Although generally considered …

Follicular lymphoma (FL) is the most frequently occurring indolent non-Hodgkin lymphoma,
with generally favorable outcomes but a variable clinical course. Recent studies have …

Follicular lymphoma is a heterogeneous B-cell lymphoma both in presentation and at
progression. For most patients it is a chronic, relapsing indolent disease with overall survival …

Follicular lymphoma (FL) is clinically heterogeneous, with select patients tolerating extended
watch-and-wait, whereas others require prompt treatment, suffer progression of disease …

A minority of patients with follicular lymphoma (FL) undergo histological transformation (HT).
This retrospective analysis of 549 patients from the phase 3 GALLIUM study …

PURPOSE Rituximab improves progression-free survival (PFS) and time to next treatment
(TTNT) when compared with the watch and wait strategy for patients with low–tumor burden …

Simple Summary In this paper, we give an overview on the classification of Follicular
lymphoma as modified in the 5th edition of the WHO classification of haematolymphoid …